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Murine leukemia virus (MuLV) clone Fr98 is a recombinant polytropic virus that causes neurological disease characterized
by ataxia in susceptible mouse strains. The envelope gene of Fr98 has been previously shown to encode at least two
separate neurovirulence determinants. In the present study, the determinant encoded within the EcoRI/AvrII fragment of the
envelope gene was further defined. In these experiments, neurovirulence was associated with a change from a serine to an
arginine at position 195 and a glycine to an alanine at position 198 within the envelope protein. Neurovirulent and nonvirulent
virus clones, which differed only at these two amino acid residues, showed no difference in the type or location of cells
infected. Furthermore, equivalent levels of viral p30 capsid protein were detected in the brains of mice infected with either
the neurovirulent or nonvirulent virus clones. These results were consistent with the interpretation that the envelope protein
of the neurovirulent virus differed from that of the nonvirulent virus by having a greater toxic effect on central nervous system
function.
INTRODUCTION
Retroviruses induce central nervous system (CNS) dis-
ease in a variety of hosts, including humans, macaques,
ruminants, cats, and rodents. The mechanisms of patho-
genesis associated with these viruses remain unclear,
and different mechanisms may be used by different vi-
ruses. For example, human T-cell leukemia virus, simian
immunodeficiency virus, Visna, and caprine arthritis-en-
cephalitis virus all induce neurological diseases associ-
ated with a marked CNS infiltration of mononuclear leu-
kocytes, which may contribute to the pathogenic process
(Georgsson et al., 1976, 1994; Izumo et al., 1997; Cork et
al., 1974). In contrast, human immunodeficiency virus
(HIV), feline immunodeficiency virus, and murine leuke-
mia viruses (MuLVs) induce CNS diseases characterized
by a more limited inflammatory response, sometimes
associated with spongiform degeneration (Georgsson,
1994; Navia et al., 1986; Wiley and Gardner, 1993). Most
neurovirulent retroviruses are capable of infecting micro-
glia within the CNS, and a number of studies have
suggested that infected macrophages and microglia (Jor-
dan et al.,1991) release toxic factors that mediate CNS
disease (Lipton, 1991; Gendelman et al., 1994). In addi-
tion to microglia, most MuLVs also infect brain capillary
endothelial cells. In the case of the ecotropic MuLV
TR1.3, the main pathological feature is hemorrhage as-
sociated with a stroke syndrome due to damage of in-
fected brain capillary endothelial cells (Park et al., 1993,
1994). In contrast, other ecotropic MuLVs that can infect
endothelia, microglia, and sometimes selected popula-
tions of neurons induce tremor and hind limb paralysis
associated with severe spongiform degeneration (Gard-
ner, 1988; Masuda et al., 1993; Lynch et al., 1991; Portis
et al., 1990; Wong et al., 1989). The polytropic MuLV
FMCF98, which was used as the basis for the present
study, causes ataxia without paralysis (Buller et al., 1990).
FMCF98 does not infect neurons but does infect brain
capillary endothelial cells and microglia primarily asso-
ciated with white matter tracts of the cerebellum and
internal capsule, resulting in minimal spongiform lesions
compared with the ecotropic MuLVs (Portis et al., 1995).
The envelope gene of FMCF98 was previously shown to
be critical for the induction of neurological disease. Inser-
tion of this gene into the nonvirulent ecotropic Friend virus
molecular clone FB29 generated the neurovirulent poly-
tropic virus clone Fr98, which induced disease at a more
rapid rate than FMCF98 (Portis et al., 1995). Previous stud-
ies identified two neurovirulence determinants within the
Fr98 envelope gene (Hasenkrug et al., 1996). The expres-
sion of either determinant alone was sufficient to induce
CNS disease. One determinant was located within an SphI/
EcoRI fragment near the 59 end of the envelope gene and
appeared to influence viral spread in microglial cells (Rob-
ertson et al.,1997). The second neurovirulence determinant
was located within an EcoRI/AvrII fragment near the center
of the envelope gene. In the present study, two amino acids
encoded within this latter region were identified as critical
determinants of neurovirulence. Furthermore, quantitative
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analysis of viral protein levels within the CNS and regional
distribution of virus indicated that these envelope amino
acid residues did not influence neurovirulence by altering
the level or localization of virus infection within the brain.
RESULTS
Envelope sequences influencing neurological disease
induced by virus clone EC
Using the coisogenic recombinant virus clones EC
and AC, which express chimeric envelope sequences
(Fig. 1), it was determined that the EcoRI/AvrII region of
the Fr98 envelope gene strongly influenced neuroviru-
lence (Hasenkrug et al., 1996). Both EC and AC were
neuroinvasive, but no signs of clinical disease were
observed after intraperitoneal inoculation of neonatal
IRW mice with virus clone AC. In contrast, at 3–4 weeks
postinfection with the EC virus clone, mice exhibited
hyperactivity characterized by repetitive jumping in the
corner of the box that could be accentuated by auditory
stimulation. At 4–5 weeks postinoculation, EC-infected
mice typically developed a progressive ataxia mani-
fested by imbalance and an awkward, uneven gait. Later,
in the preterminal stage of disease, mice occasionally
exhibited intermittent seizure-like episodes character-
ized by torticollis and muscle rigidity, which led to immo-
bility and an exhausted appearance. Virus-infected mice
that survived past 13 weeks had a gradually increased
incidence of leukemia (Buller et al., 1990). Therefore,
analysis of CNS disease was terminated at 13 weeks in
subsequent experiments.
Because the virus clones EC and AC differed only at 17
amino acid residues between positions 186 and 323 of
the envelope protein (Hasenkrug et al., 1996), we were
interested in determining which of these sequence dif-
ferences influenced neurovirulence. Therefore, a series
of seven coisogenic recombinant virus clones was cre-
ated in which specific sequences from the nonvirulent
AC virus were substituted into the EcoRI/AvrII region of
the neurovirulent EC virus envelope gene (Fig. 2). All
virus constructs were viable and replicated in vitro to
titers of ;105 FFU/ml. Virus replication in vivo was con-
firmed by measuring plasma viremia titers at 19 days
after intraperitoneal inoculation of neonatal IRW mice
with ;102 to 103 FFU of virus. All recombinant viruses
induced plasma viremia titers in the range of 104 to 105
FFU/ml.
The seven recombinant viruses were observed to dif-
fer in their ability to cause CNS dysfunction (Fig. 2). Virus
clones EC-25, EC-35, and EC-45 induced ataxia in 14–
38% of the mice inoculated. In contrast, ataxia was never
observed in mice infected with the virus clones EC-1,
EC-12, EC-13, or EC-14. Thus, sequence within the ex-
treme 59 end of the EcoRI/AvrII fragment appeared to
influence neurovirulence. However, the incidence of dis-
ease observed in mice infected with EC-25, EC-35, and
EC-45 was lower than that induced by the parental virus
clone EC (Fig. 2). This suggested that additional se-
quences within the 39 portion of the EcoRI/AvrII region
might be required to induce an incidence of disease
equivalent to EC. Alternatively, the difference in disease
incidence could have simply been due to the 10-fold
range in the virus doses inoculated (Fig. 2).
To resolve this question, newborn IRW mice were
inoculated with 104 FFU of selected virus clones. Under
these conditions, the incidences of disease induced by
EC and EC-25 were equivalent (Fig. 2). In addition, a
similar pattern of disease kinetics was observed in mice
infected with EC and EC-25 (Fig.3). Within 5 weeks
postinfection, 100% of the mice infected with EC or EC-25
developed severe ataxia and progressed to a pretermi-
nal stage by 4–6 weeks postinfection. In contrast, none
of the mice inoculated with 104 FFU of AC or EC-1
developed ataxia (Figs. 2 and 3). The envelope gene
sequence of virus clone EC-1 differed from the neuro-
virulent EC virus at only two amino acid codons. Like-
wise, the neurovirulent virus clone EC-25 differed from
the nonvirulent clone AC only at these same two codons
(Fig. 2). Both the nonvirulent clones AC and EC-1 en-
coded serine at position 195 and glycine at position 198
of the envelope protein, whereas the neurovirulent
clones EC and EC-25 encoded arginine at position 195
and alanine at 198 (Fig. 2). These results indicated that
FIG. 1. Influence of the EcoRI/AvrII fragment on neurovirulence. The 2.45-kb SphI/ClaI fragment of parental (Fr98 and Fr54) and chimeric viruses
(AC and EC) are shown. The percent of mice that exhibited ataxia at 2–5 weeks after infection with each virus is indicated (right). The number of mice
with ataxia over the total in each group is shown in parentheses.
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neurovirulence was strongly influenced by this small
region of the envelope protein.
Detection of viral p30 capsid protein
In a recent study examining the recombinant poly-
tropic virus clones SE and Fr54, which differ only at 12
amino acid residues encoded within the SphI/EcoRI frag-
ment of the envelope gene, a correlation was observed
between the level of viral p30 capsid protein detected in
the cerebellum of infected mice and the induction of CNS
disease (Robertson et al., 1997). Therefore, we were
interested in determining whether a similar correlation
could explain the differences in neurovirulence observed
among the virus clones used in this study.
To examine this possibility, cerebellar homogenates
were prepared from mice infected with 104 FFU of se-
lected virus clones. The level of virus present in each
sample was determined by immunoblot analysis of virus
p30 capsid protein (Fig.4). At the time of sacrifice, all the
mice infected with the neurovirulent virus clones exhib-
ited ataxia, whereas none of the mice infected with the
nonvirulent clones showed signs of disease. No statisti-
cally significant differences in the levels of p30 were
detected in cerebellar homogenates from mice infected
with the neurovirulent clones EC or EC-25 compared with
mice infected with the nonvirulent clones EC-1 or Fr54
(Fig. 4). In fact, slightly higher levels of p30 were detected
in mice infected with the nonvirulent clone AC compared
with those infected with EC or EC-25.
The results of the immunoblot analysis suggested that
the induction of CNS disease by the EC virus clone did
not correlate with an increase in the amount of viral
protein detected. To confirm these results with a more
sensitive and quantitative assay, virus p30 levels present
in both cerebellar and cerebral homogenates from ataxic
EC-infected mice and healthy age-matched EC-1-in-
fected mice were examined by antigen capture ELISA at
FIG. 2. Influence of specific envelope amino acids on neurovirulence. Map of the 410-bp EcoRI/AvrII fragment showing the specific amino acid
differences encoded by the virulent EC virus, nonvirulent AC virus, and mutant virus clones. The percent of ataxic mice observed after infection of
neonatal IRW mice with 102 to 104 FFU of virus is indicated (right). The number of mice with ataxia over the total in each group is shown in
parentheses.
FIG. 3. Kinetics of CNS disease induced after intraperitoneal injec-
tion of neonatal IRW mice with 104 FFU of recombinant polytropic
viruses. The percentage of mice exhibiting ataxia in each experimental
group is shown relative to time postinfection.
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5 weeks postinfection. Homogenates from ataxic SE-
infected mice, shown previously to have high levels of
viral p30 in the cerebellum (Robertson et al., 1997), were
used as additional controls. No statistically significant
differences were observed between the levels of virus
p30 present in either the cerebellum or cerebrum of mice
infected with EC or EC-1 (Fig. 5). In contrast, compared
with EC and EC-1, SE-infected mice had a threefold
increase in viral p30 in cerebellar homogenates and a
slight but statistically significant increase in the level of
p30 in cerebral homogenates. These results confirmed
the results of immunoblot analysis and indicated that EC
and EC-1 replicated to equivalent levels within the cer-
ebellum and cerebrum yet differed dramatically in neu-
rovirulence.
Immunohistochemical analysis of viral envelope
One possible explanation for the difference in neuro-
virulence observed between EC and EC-1 was that
changes in the envelope sequence might have allowed
these two viruses to infect different cell types or sub-
populations of cells within different regions of the brain.
To examine this possibility, immunohistochemical analy-
sis was performed on brain sections from ataxic, EC-
infected or age-matched, healthy EC-1-infected mice
FIG. 4. (A) Western blot analysis of virus p30 antigen levels present in 10% cerebellar homogenates. The virus clones used in each infection are
indicated above the gel. Samples from SE-infected mice were included as high virus level controls. Three to five mice per virus clone were sacrificed
at 5 weeks postinfection. All mice infected with neurovirulent virus clones exhibited ataxia at the time of sacrifice, whereas all mice infected with
nonvirulent virus clones were healthy. (B) Relative amount of viral p30 antigen present in brain samples as measured by quantitative fluorescence
analysis for mice infected with each of the viruses indicated. The ability of each virus to induce ataxia is shown (left). The mean values and standard
deviations for each group are shown (right).
FIG. 5. Detection of virus p30 by antigen capture enzyme-linked
immunosorbent assay. The concentrations of virus p30 present in 10%
cerebral and cerebellar homogenates from 5-week-old, ataxic EC- or
SE-infected mice or healthy age-matched EC-1-infected mice are
shown. Each point represents a single mouse, and bars represent the
standard deviation of replicate determinations.
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(Fig. 6A). No difference was observed in the distribution
or apparent type of cells infected by either EC or EC-1.
Virus envelope expression was detected primarily in
highly arborized cells, reminiscent of microglia that have
been previously shown to be infected by both Fr98 and
Fr54 (Robertson et al., 1997). Vascular endothelial cells
FIG. 6. Immunohistochemical staining of horizontal brain sections from ataxic EC-infected or healthy age-matched EC-1-infected mice. (A) Infected
cells were detected using goat anti-gp70 antibody. (B) Activated astrocytes expressing GFAP were detected with rabbit anti-GFAP antibody, as
detailed in Materials and Methods.
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were also infected to a lesser extent by both viruses.
EC-and EC-1-infected cells were mostly associated with
the white matter tracts of the internal capsule and cere-
bellum but also, to a lesser extent, within the lateral
thalamic nucleus and the CA4 region of the hippocam-
pus. Thus, both viruses appeared to infect the same cell
types within the same regions of the brain.
Detection of activated astrocytes
Astrocyte activation is one of the earliest responses
after CNS injury (Norenberg, 1994). To examine whether
astrocyte activation differed in EC-versus EC-1-infected
mice, brain sections adjacent to those examined for virus
envelope expression were stained for the astrocyte ac-
tivation marker GFAP. Immunohistochemical analysis in-
dicated that GFAP-positive astrocytes colocalized to re-
gions of the brain infected by EC and EC-1. Furthermore,
as shown in Figure 6B, infection with either EC or EC-1
resulted in similar levels of astrocytosis and GFAP ex-
pression. These results were similar to those observed
previously for the avirulent virus clone Fr54 and the
neurovirulent clone Fr98 (Robertson et al., 1997) and
suggest that astrocytosis is not a pathological correlate
of clinical CNS disease in this case but rather a re-
sponse to viral infection.
DISCUSSION
In the present experiments, expression of specific
amino acid residues at positions 195 and 198 of the
polytropic MuLV envelope protein was found to strongly
influence neurovirulence. To gain insight into how these
residues might affect disease induction, we examined
their relationship with previously defined domains within
the polytropic MuLV envelope protein. Residues 195 and
198 did not lie within the defined VRA, VRB, or VRC
receptor binding domains, nor were they associated with
the proline-rich region (Battini et al., 1995). Thus, these
residues may not play a direct role in receptor interac-
tions. We also compared the predicted EC and EC-1
envelope protein secondary structures with the known
secondary structure of the recently published crystallo-
graphic analysis of the N-terminal 236-amino-acid resi-
dues from the ecotropic MuLV envelope protein (Fass et
al., 1997; Rost et al., 1993, 1994). Indeed, the predicted
secondary structures of the EC and EC-1 envelopes
showed considerable similarity with the common immu-
noglobulin-like core stalk of the ecotropic envelope pro-
tein composed of an antiparallel b sandwich (Dimitrov,
1997; Fass et al., 1997). Based on this comparison, the
amino acid residues at positions 195 and 198 in the EC
and EC-1 envelope proteins were predicted to reside
within a short a-helical loop located on the opposite side
of the monomeric molecule from the receptor binding
elements. Given the predicted location of residues 195
and 198, they could interact with the stalk of an adjacent
molecule in the mature envelope complex, which exists
as a trimer. In this way, residues at these positions might
influence the processing and stability of the mature tri-
meric molecule. Indeed, a similar mechanism has been
proposed to explain the effect of a valine-to-isoleucine
change at position 25 within the envelope protein of the
neurovirulent ecotropic MuLV ts 1 (Kamps et al., 1991; Yu
and Wong, 1992).
The neurovirulent virus clone EC and the nonvirulent
clone EC-1 both infected similar populations of microglia
and replicated to equivalent levels within the cerebellum
and cerebrum (Figs. 5 and 6A). Furthermore, the levels of
viral protein detected in the CNS of mice infected with EC
or EC-1 were comparable with the lower levels of virus
protein detected in the brains of mice infected with the
nonvirulent clone Fr54. Under these conditions of rela-
tively low viral protein and equal levels of infection, two
alternatives may explain the difference in neurovirulence
between EC and EC-1. First, nonvirulent virus clones
such as EC-1 may stimulate a protective response that
the EC envelope is unable to induce. For example, it has
been suggested that astrocytes may play a role in limit-
ing MuLV-induced pathology within the CNS (Lynch et
al., 1995). Thus, the envelope sequence from EC-1 may
induce a more robust protective response from astro-
cytes. However, we did not observe any major differ-
ences in the levels of astrocyte activation as assessed
by GFAP expression after infection with either EC or
EC-1. The second possible explanation for the difference
in neurovirulence is that the EC envelope protein might
be more neurotoxic than the EC-1 envelope protein. The
EC envelope protein itself might be directly toxic to
neurons or, alternatively, the EC envelope protein might
indirectly mediate neurovirulence by altering the neuro-
toxins produced by infected microglia (Fig. 6A) or nearby
uninfected, activated astrocytes (Fig. 6B).
Results from in vitro studies have suggested a number
of ways in which retrovirus envelope proteins might
influence neurovirulence. For example, it has been re-
ported that the HIV gp120 envelope protein can predis-
pose cultured cerebellar neurons to N-methyl-D-aspar-
tate-mediated neurotoxicity by causing an increase in
the intracellular Ca21 concentration (Lannuzel et al.,
1995; Lipton, 1994). HIV gp120 has also been shown to
both inhibit the uptake and induce the release of gluta-
mate by astrocytes (Dreyer and Lipton, 1995; Vesce et al.,
1997). It is possible the EC envelope protein influences
neurovirulence through similar mechanisms.
Although differences in the levels of viral p30 protein
were detected in the cerebellums of mice infected with
SE and EC virus clones, no obvious differences were
observed in the clinical disease produced by these two
viruses. Mice infected with either the EC or SE virus
clones exhibited similar neuromotor deficits, as well as
the same incidence and rate of disease progression
(Hasenkrug et al., 1996). Furthermore, the disease-induc-
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ing effects of the EC and SE neurovirulence determinants
appeared to be additive in that expression of both deter-
minants by the virus clone Fr98 resulted in an accelera-
tion of CNS disease induction (Hasenkrug et al., 1996).
This complementation might be expected if the in-
creased level of virus infection induced by the SE deter-
minant further amplified the virulent effects of the EC
determinant, resulting in a more rapid kinetics of dis-
ease. However, more precise knowledge of the mecha-
nisms of both of these determinants will be required to
explain their cooperative effects in vivo.
MATERIALS AND METHODS
Construction of recombinant viruses
All recombinant clones were derived from the BC3
plasmid that contained the SphI/ClaI fragment encoding
the env gene of EC inserted into the cloning vector
pSP72 (Promega). The construction of virus clones EC,
AC, Fr54, and FR98 has been previously described
(Hasenkrug et al., 1996). Specific amino acid coding
changes were introduced into EC by overlapping poly-
merase chain reaction mutagenesis. Sequence changes
were confirmed by double-stranded sequence analysis.
SphI/ClaI fragments containing the altered env se-
quences were subcloned into the nonneurovirulent virus
clone FB29 (Hasenkrug et al., 1996), in which the SphI/
ClaI fragment had been replaced with a short polylinker
composed of multiple restriction enzyme digestion sites.
Virus stocks were prepared by transfecting mus dunni
fibroblasts with the plasmid DNA of recombinant clones
and harvesting supernatants from confluently infected
cultures. Virus titers were determined by a focal infectiv-
ity assay (Sitbon et al., 1985) using the envelope specific
monoclonal antibody 720 (Robertson et al., 1991). For
viremia titration, 19-day-old mice were anesthetized by
methoxyflurane inhalation and bled by retroorbital punc-
ture. Blood was collected in heparinized capillary tubes,
and plasma was separated by centrifugation, stored on
ice, and diluted for immediate titration by the focal infec-
tivity assay (Sitbon et al., 1985).
Animals and clinical disease
Inbred Rocky Mountain White (IRW) mice were bred
and housed at the Rocky Mountain Laboratories animal
facility. Within 24 h after birth, mice were injected intra-
peritoneally with various doses of viruses as detailed
within each experiment. Mice were observed daily for
clinical signs of CNS disease as previously described
(Portis et al., 1995). All animal experiments were done in
accordance with the standards established by the Rocky
Mountain Laboratory Animal Care and Use Committee
and the National Institutes of Health.
Immunoblotting
Western blot analysis was performed as previously
described (Robertson et al., 1997). Viral p30 capsid pro-
tein was detected using the rat monoclonal antibody
R187 (Chesebro et al., 1983) followed by an alkaline
phosphatase-conjugated goat anti-rat IgG (Southern Bio-
technology Associates) and developed with the Vistra
ECF (enhanced chemifluorescence) system (Amersham
Life Science). The fluorescence intensities of specific
bands were quantified using the Storm 860 image anal-
ysis system and ImageQuant software (Molecular Dy-
namics).
Capture enzyme-linked immunosorbent assay
Viral p30 capsid protein levels present in 10% (w/v)
brain homogenates were quantified as previously de-
scribed (Wehrly and Chesebro, 1997). The anti-p30 rat
monoclonal antibody R187 was used as the capture
antibody (Chesebro et al., 1983). Bound p30 was then
detected with rabbit anti-p30 antiserum (Lynch and Por-
tis, 1993) and a secondary donkey anti-rabbit antibody
conjugated to horseradish peroxidase (HRP; Amersham
Life Science). The total protein concentration present in
each brain homogenate (either whole cerebellum or one
half of the cerebrum) was determined by measuring the
A205nm in a solution of 0.01% Brij 35 (Sigma Chemical)
dissolved in distilled water. Equivalent amounts of total
protein were assayed for each brain homogenate. The
p30 levels present in four serial dilutions from each brain
homogenate were compared in triplicate against a dilu-
tion series standard. The standard used was the neuro-
virulent ecotropic MuLV KP (Portis et al., 1994) that had
been purified by sucrose density gradient centrifugation.
The purified KP standard was determined to have a total
protein concentration of 580 mg/ml. To determine the
percentage of p30 present in the virus standard, viral
proteins were separated on a 12.5% sodium dodecyl
sulfate-polyacrylamide gel and stained with SYPRO-red
(Molecular Probes). The relative fluorescence intensities
of each protein band within the standard was quantified
as before using the Storm 860 image analysis system
and ImageQuant software (Molecular Dynamics). Under
these conditions, p30 was determined to represent
;40% of the total proteins present in the standard.
Immunohistochemistry
Brains were collected from 4-week-old ataxic EC-in-
fected mice or healthy EC-1-infected mice. Animals were
perfused with 4% formaldehyde in phosphate-buffered
saline (PBS), and brains were postfixed for an additional
4 h in 4% formaldehyde in PBS at 4°C. Paraffin-embed-
ded brains were cut into 8-mm-thick sections and pre-
pared for staining for virus envelope protein or GFAP.
After the removal of paraffin, sections to be stained for
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virus envelope protein were incubated at 100°C in citrate
buffer (pH 6.0) for 20 min to reactivate antigens masked
by fixation (McQuaid et al., 1995; Usuda et al., 1996; Yang
et al., 1995). Sections were blocked in PBS with 5%
bovine serum albumin overnight at 4°C and then washed
in PBS. Virus envelope was detected by incubating each
section for 1 h at 37°C with a goat anti-gp70 antibody
(kindly provided by Roland Friedrich, Institute of Medical
Virology, Geissen, Germany) diluted 1:2000 in PBS con-
taining 5% fetal calf serum. Sections were washed and
reacted for 1 h at 37°C with a secondary rabbit anti-goat
antibody conjugated to HRP (ICN Biochemicals Inc.) that
had been diluted 1:250 in PBS with 5% bovine serum
albumin. Sections were washed and reacted with 3-ami-
no-9-ethylcarbazole (AEC) as a substrate for HRP (Rob-
ertson et al., 1997) for 10 min and counterstained with
Harris hematoxylin.
GFAP staining was performed on paraffin-embedded
sections with primary rabbit anti-GFAP antibody diluted
1:2000 in PBS with 5% fetal calf serum (Dakopatts) fol-
lowed by a secondary goat anti-rabbit conjugated to HRP
(BioRad) diluted 1:250. GFAP-positive cells were visual-
ized by reacting sections with AEC and counterstained
with Harris hematoxylin.
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